{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:22:30Z","timestamp":1791994950402,"version":"4.4.0"},"update-to":[{"DOI":"10.1371\/journal.pmed.1003875","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000}}],"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL144406"],"award-info":[{"award-number":["R01HL144406"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Scaling up shorter regimens for tuberculosis (TB) prevention such as once weekly isoniazid\u2013rifapentine (3HP) taken for 3 months is a key priority for achieving targets set forth in the World Health Organization\u2019s (WHO) END TB Strategy. However, there are few data on 3HP patient acceptance and completion in the context of routine HIV care in sub-Saharan Africa.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and findings<\/jats:title>\n<jats:p>The 3HP Options Trial is a pragmatic, parallel type 3 effectiveness\u2013implementation randomized trial comparing 3 optimized strategies for delivering 3HP\u2014facilitated directly observed therapy (DOT), facilitated self-administered therapy (SAT), or informed choice between DOT and SAT using a shared decision-making aid\u2014to people receiving care at a large urban HIV clinic in Kampala, Uganda. Participants and healthcare providers were not blinded to arm assignment due to the nature of the 3HP delivery strategies. We conducted an interim analysis of participants who were enrolled and exited the 3HP treatment period between July 13, 2020 and April 30, 2021. The primary outcome, which was aggregated across trial arms for this interim analysis, was the proportion who accepted and completed 3HP (\u226511 of 12 doses within 16 weeks of randomization). We used Bayesian inference analysis to estimate the posterior probability that this proportion would exceed 80% under at least 1 of the 3HP delivery strategies, a coprimary hypothesis of the trial. Through April 2021, 684 participants have been enrolled, and 479 (70%) have exited the treatment period. Of these 479 participants, 309 (65%) were women, mean age was 41.9 years (standard deviation (SD): 9.2), and mean time on antiretroviral therapy (ART) was 7.8 years (SD: 4.3). In total, 445 of them (92.9%, 95% confidence interval (CI): [90.2 to 94.9]) accepted and completed 3HP treatment. There were no differences in treatment acceptance and completion by sex, age, or time on ART. Treatment was discontinued due to a documented adverse event (AE) in 8 (1.7%) patients. The probability that treatment acceptance and completion exceeds 80% under at least 1 of the three 3HP delivery strategies was greater than 99%. The main limitations are that the trial was conducted at a single site, and the interim analysis focused on aggregate outcome data to maintain blinding of investigators to arm-specific outcomes.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>3HP was widely accepted by people living with HIV (PLHIV) in Uganda, and very high levels of treatment completion were achieved in a programmatic setting. These findings show that 3HP can enable effective scale-up of tuberculosis preventive therapy (TPT) in high-burden countries, particularly when delivery strategies are tailored to target known barriers to treatment completion.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Trial registration<\/jats:title>\n<jats:p>ClinicalTrials.gov <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03934931\" xlink:type=\"simple\">NCT03934931<\/jats:ext-link>.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pmed.1003875","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T18:53:32Z","timestamp":1639680812000},"page":"e1003875","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":23,"title":["Completion of isoniazid\u2013rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness\u2013implementation randomized trial"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0624-7640","authenticated-orcid":true,"given":"Fred C.","family":"Semitala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4568-8681","authenticated-orcid":true,"given":"Jillian L.","family":"Kadota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Musinguzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Nabunje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Welishe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8198-6681","authenticated-orcid":true,"given":"Anne","family":"Nakitende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Akello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Opira","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1479-3588","authenticated-orcid":true,"given":"Devika","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8044-7165","authenticated-orcid":true,"given":"Amanda","family":"Sammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2811-1311","authenticated-orcid":true,"given":"Payam","family":"Nahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Belknap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses R.","family":"Kamya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret A.","family":"Handley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-7024","authenticated-orcid":true,"given":"Patrick P. J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3520-070X","authenticated-orcid":true,"given":"Anne","family":"Katahoire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0034-7544","authenticated-orcid":true,"given":"Christopher A.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2471-9290","authenticated-orcid":true,"given":"Noah","family":"Kiwanuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2347-4183","authenticated-orcid":true,"given":"Achilles","family":"Katamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0481-7475","authenticated-orcid":true,"given":"David W.","family":"Dowdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adithya","family":"Cattamanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,12,16]]},"reference":[{"key":"pmed.1003875.ref001","unstructured":"World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization; 2020."},{"issue":"9","key":"pmed.1003875.ref002","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1507198","article-title":"A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa","volume":"373","author":"TAS Group","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"pmed.1003875.ref003","doi-asserted-by":"crossref","first-page":"e1080","DOI":"10.1016\/S2214-109X(17)30372-8","article-title":"Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial","volume":"5","author":"A Badje","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"12","key":"pmed.1003875.ref004","doi-asserted-by":"crossref","first-page":"329","DOI":"10.15585\/mmwr.mm6912a3","article-title":"Tuberculosis Preventive Treatment Scale-Up Among Antiretroviral Therapy Patients\u201416 Countries Supported by the U.S. President\u2019s Emergency Plan for AIDS Relief, 2017\u20132019","volume":"69","author":"M Melgar","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"pmed.1003875.ref005","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1186\/s12889-020-09902-z","article-title":"Evaluation of the uptake of tuberculosis preventative therapy for people living with HIV in Namibia: a multiple methods analysis","volume":"20","author":"C Roscoe","year":"2020","journal-title":"BMC Public Health"},{"issue":"11","key":"pmed.1003875.ref006","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","article-title":"The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis","volume":"16","author":"H Alsdurf","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"23","key":"pmed.1003875.ref007","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"TR Sterling","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"pmed.1003875.ref008","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1005136","article-title":"New regimens to prevent tuberculosis in adults with HIV infection","volume":"365","author":"NA Martinson","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"pmed.1003875.ref009","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/cid\/ciw126","article-title":"Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada","volume":"62","author":"RN Moro","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"10","key":"pmed.1003875.ref010","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/M17-1150","article-title":"Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial","volume":"167","author":"R Belknap","year":"2017","journal-title":"Ann Intern Med"},{"issue":"5","key":"pmed.1003875.ref011","doi-asserted-by":"crossref","first-page":"e1135","DOI":"10.1093\/cid\/ciaa1835","article-title":"Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting","volume":"73","author":"CM Yuen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"pmed.1003875.ref012","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.ijid.2020.02.034","article-title":"Management of latent tuberculosis infection in China: Exploring solutions suitable for high-burden countries","volume":"92S","author":"X Cui","year":"2020","journal-title":"Int J Infect Dis"},{"key":"pmed.1003875.ref013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-publhealth-031816-044215","article-title":"An Overview of Research and Evaluation Designs for Dissemination and Implementation","volume":"38","author":"CH Brown","year":"2017","journal-title":"Annu Rev Public Health"},{"issue":"1","key":"pmed.1003875.ref014","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13012-020-01025-8","article-title":"Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda","volume":"15","author":"JL Kadota","year":"2020","journal-title":"Implement Sci"},{"issue":"7","key":"pmed.1003875.ref015","doi-asserted-by":"crossref","first-page":"729","DOI":"10.5588\/ijtld.20.0010","article-title":"Willingness to accept reimbursement for visits to an HIV clinic for tuberculosis preventive therapy","volume":"24","author":"JL Kadota","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"pmed.1003875.ref016","doi-asserted-by":"crossref","first-page":"e0246113","DOI":"10.1371\/journal.pone.0246113","article-title":"Patient choice improves self-efficacy and intention to complete tuberculosis preventive therapy in a routine HIV program setting in Uganda","volume":"16","author":"RK Lim","year":"2021","journal-title":"PLoS ONE"},{"key":"pmed.1003875.ref017","article-title":"Acceptance and completion of rifapentine based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda\u2014patient and health worker perspectives","volume":"2","author":"FC Semitala","year":"2021","journal-title":"Implementation Science. IDAA Commun"},{"issue":"5","key":"pmed.1003875.ref018","doi-asserted-by":"crossref","first-page":"e001018","DOI":"10.1136\/bmjgh-2018-001018","article-title":"Digital adherence technologies for the management of tuberculosis therapy: mapping the landscape and research priorities","volume":"3","author":"R Subbaraman","year":"2018","journal-title":"BMJ Glob Health"},{"issue":"9","key":"pmed.1003875.ref019","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.2105\/AJPH.89.9.1322","article-title":"Evaluating the public health impact of health promotion interventions: the RE-AIM framework","volume":"89","author":"RE Glasgow","year":"1999","journal-title":"Am J Public Health"},{"key":"pmed.1003875.ref020","volume-title":"Bayesian data analysis","author":"A Gelman","year":"2014"},{"key":"pmed.1003875.ref021","unstructured":"Global Multidimensional Poverty index 2020 \u2013Charting Pathways out of Multidimensional Poverty: Achieving the SDGs. UNDP and OPHI. 2020."},{"issue":"4","key":"pmed.1003875.ref022","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/jac\/dkt483","article-title":"Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers","volume":"69","author":"M Weiner","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"pmed.1003875.ref023","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/cid\/civ464","article-title":"Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention","volume":"61","author":"AT Podany","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"7","key":"pmed.1003875.ref024","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/cid\/cix505","article-title":"High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection","volume":"65","author":"AL Sandul","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pmed.1003875.ref025","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/1060028019888855","article-title":"Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection","volume":"54","author":"RE Walker","year":"2020","journal-title":"Ann Pharmacother"},{"key":"pmed.1003875.ref026","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.tube.2018.05.013","article-title":"Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan","volume":"111","author":"HY Sun","year":"2018","journal-title":"Tuberculosis (Edinb)"},{"key":"pmed.1003875.ref027","article-title":"Higher Completion Rates with Self-administered Once-weekly Isoniazid-Rifapentine versus Daily Rifampin in Adults with Latent Tuberculosis","author":"MK Haas","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pmed.1003875.ref028","article-title":"Annual Tuberculosis Preventive Therapy for Persons With HIV Infection: A Randomized Trial","author":"G Churchyard","year":"2021","journal-title":"Ann Intern Med"},{"key":"pmed.1003875.ref029","unstructured":"Consolidated Guidelines for the Prevention and Treatment of HIV and AIDS in Uganda. In: Ministry of Health, Kampala, Uganda. 2020."},{"issue":"1","key":"pmed.1003875.ref030","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12889-020-10098-5","article-title":"Toward patient-centered tuberculosis preventive treatment: preferences for regimens and formulations in Lima, Peru","volume":"21","author":"CM Yuen","year":"2021","journal-title":"BMC Public Health"},{"issue":"Suppl 5","key":"pmed.1003875.ref031","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1097\/01.aids.0000391023.03037.1f","article-title":"Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions","volume":"24","author":"H Getahun","year":"2010","journal-title":"AIDS"},{"issue":"7","key":"pmed.1003875.ref032","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1080\/09540121.2017.1283390","article-title":"\"It\u2019s about my life\": facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa","volume":"29","author":"KB Jacobson","year":"2017","journal-title":"AIDS Care"},{"issue":"3","key":"pmed.1003875.ref033","first-page":"263","article-title":"Adherence to TB preventive therapy for HIV-positive patients in rural South Africa: implications for antiretroviral delivery in resource-poor settings?","volume":"9","author":"KA Rowe","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"pmed.1003875.ref034","doi-asserted-by":"crossref","first-page":"26","DOI":"10.11604\/pamj.2014.17.26.2641","article-title":"Perceived barriers to the implementation of Isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study","volume":"17","author":"M Mindachew","year":"2014","journal-title":"Pan Afr Med J"},{"issue":"4","key":"pmed.1003875.ref035","doi-asserted-by":"crossref","first-page":"396","DOI":"10.5588\/ijtld.18.0740","article-title":"Priorities among HIV-positive individuals for tuberculosis preventive therapies","volume":"24","author":"HY Kim","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"pmed.1003875.ref036","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.5588\/ijtld.12.0240","article-title":"A qualitative assessment of challenges to tuberculosis management and prevention in Northern Ethiopia","volume":"17","author":"J Cowan","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"pmed.1003875.ref037","doi-asserted-by":"crossref","first-page":"e18435","DOI":"10.1371\/journal.pone.0018435","article-title":"Risk factors for non-adherence and loss to follow-up in a three-year clinical trial in Botswana","volume":"6","author":"DA Gust","year":"2011","journal-title":"PLoS ONE"},{"issue":"2","key":"pmed.1003875.ref038","doi-asserted-by":"crossref","first-page":"e87166","DOI":"10.1371\/journal.pone.0087166","article-title":"Factors associated with adherence to treatment with isoniazid for the prevention of tuberculosis amongst people living with HIV\/AIDS: a systematic review of qualitative data","volume":"9","author":"T Makanjuola","year":"2014","journal-title":"PLoS ONE"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1003875","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003875","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T18:36:45Z","timestamp":1641321405000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003875"}},"subtitle":[],"editor":[{"given":"Claudia M.","family":"Denkinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,12,16]]},"references-count":38,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1003875","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pmed.1003875","asserted-by":"object"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,16]]}}}